BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 18554756)

  • 21. [The effect of ribozyme RzDS on duck hepatitis B virus].
    Li H; Chen W; Xu W
    Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi; 1998 Jun; 12(2):118-21. PubMed ID: 12515186
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Covalently closed circular DNA is the predominant form of duck hepatitis B virus DNA that persists following transient infection.
    Le Mire MF; Miller DS; Foster WK; Burrell CJ; Jilbert AR
    J Virol; 2005 Oct; 79(19):12242-52. PubMed ID: 16160150
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Delipidation of a hepadnavirus: Viral inactivation and vaccine development.
    Cham BE; Vickery K; Tohidi-Esfahani R; Cossart Y
    J Virol Methods; 2006 Oct; 137(1):160-3. PubMed ID: 16808980
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Bicistronic woodchuck hepatitis virus core and gamma interferon DNA vaccine can protect from hepatitis but does not elicit sterilizing antiviral immunity.
    Wang J; Gujar SA; Cova L; Michalak TI
    J Virol; 2007 Jan; 81(2):903-16. PubMed ID: 17079319
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Comparison of specific immune responses to duck hepatitis B virus in infected, immune, and uninfected ducks].
    Tang N; Huang A; Guo S; Qi Z; Zhang D
    Zhonghua Gan Zang Bing Za Zhi; 2001 Jun; 9(3):166-8. PubMed ID: 11412394
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Identification of antigenic regions of duck hepatitis B virus core protein with antibodies elicited by DNA immunization and chronic infection.
    Thermet A; Robaczewska M; Rollier C; Hantz O; Trepo C; Deleage G; Cova L
    J Virol; 2004 Feb; 78(4):1945-53. PubMed ID: 14747559
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cellular immune response of ducks to duck hepatitis B virus infection.
    Vickery K; Cossart Y; Dixon R
    J Med Virol; 1999 May; 58(1):19-25. PubMed ID: 10223541
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Identification of T-cell epitopes associated with immunity within the surface protein of duck hepatitis B virus.
    Welschinger R; Cossart Y; Pouliopoulos J; Dixon R; Vickery K
    J Viral Hepat; 2006 Aug; 13(8):515-22. PubMed ID: 16901281
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Establishment of an in vivo model for duck hepatitis B virus infection using Hubei duckling].
    Hu Q; Fang Y; Zhang ZM; Zhang XY; Zhang ZH; Yang DL
    Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi; 2008 Apr; 22(2):113-5. PubMed ID: 18574531
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Antisense oligodeoxynucleotide targeted at the pre-s region of DHBV could inhibit virus replication in vivo].
    He L; Wu X; Chen C
    Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi; 1998 Mar; 12(1):1-4. PubMed ID: 12515159
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Early life humoral response of ducks to DNA immunization against hepadnavirus large envelope protein.
    Rollier C; Charollois C; Jamard C; Trepo C; Cova L
    Vaccine; 2000 Jul; 18(27):3091-6. PubMed ID: 10856788
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Anti-virus effect of hepatocyte stimulating substance (HSS) on duck hepatitis B virus in vivo].
    Chen G; Chen J; Liu D; Zhang X; Zhu C; Li Y; Wang L; Yang Y; Cai G; Han F
    Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi; 1997 Dec; 11(4):329-32. PubMed ID: 15617240
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Elimination of immune tolerance to hepatitis virus in an animal model.
    Wen YM; Zhang W; Xu YY; Luo YF; Li PY
    Chin Med J (Engl); 1992 Mar; 105(3):199-203. PubMed ID: 1395838
    [TBL] [Abstract][Full Text] [Related]  

  • 34. In vivo selection of duck hepatitis B virus pre-S variants which escape from neutralization.
    Sunyach C; Chassot S; Jamard C; Kay A; Trepo C; Cova L
    Virology; 1997 Aug; 234(2):291-9. PubMed ID: 9268160
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Alternative methods for validation of cell culture infection with duck hepatitis B virus.
    Sauerbrei A; Schacke M; Schultz U; Egerer R; Merkle I; Glebe D; Gerlich W; Wutzler P
    J Virol Methods; 2005 Nov; 129(2):178-85. PubMed ID: 16002155
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cationic transfersomes based topical genetic vaccine against hepatitis B.
    Mahor S; Rawat A; Dubey PK; Gupta PN; Khatri K; Goyal AK; Vyas SP
    Int J Pharm; 2007 Aug; 340(1-2):13-9. PubMed ID: 17446015
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Epitope-specific antibody response to the surface antigen of duck hepatitis B virus in infected ducks.
    Cheung RC; Trujillo DE; Robinson WS; Greenberg HB; Marion PL
    Virology; 1990 Jun; 176(2):546-52. PubMed ID: 1693247
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The early host innate immune response to duck hepatitis B virus infection.
    Tohidi-Esfahani R; Vickery K; Cossart Y
    J Gen Virol; 2010 Feb; 91(Pt 2):509-20. PubMed ID: 19846670
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Rise in gamma interferon expression during resolution of duck hepatitis B virus infection.
    Narayan R; Buronfosse T; Schultz U; Chevallier-Gueyron P; Guerret S; Chevallier M; Saade F; Ndeboko B; Trepo C; Zoulim F; Cova L
    J Gen Virol; 2006 Nov; 87(Pt 11):3225-3232. PubMed ID: 17030856
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Antiviral effect of adefovir in combination with a DNA vaccine in the duck hepatitis B virus infection model.
    Le Guerhier F; Thermet A; Guerret S; Chevallier M; Jamard C; Gibbs CS; Trépo C; Cova L; Zoulim F
    J Hepatol; 2003 Mar; 38(3):328-34. PubMed ID: 12586299
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.